NCT04150289
Completed
Not Applicable
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
ConditionsMultiple Myeloma
DrugsFarydak
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- pharmaand GmbH
- Enrollment
- 248
- Locations
- 7
- Primary Endpoint
- Response to treatment
Overview
Brief Summary
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
Study Design
- Study Type
- Observational
- Observational Model
- Ecologic Or Community
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Willing and able to provide written informed consent
- •At least 18 years of age
- •Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
- •Initiating panobinostat within 60 days of enrollment
- •ECOG performance status 0-1
- •Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
- •Willing and able to complete the PRO questionnaire
Exclusion Criteria
- •Diagnosed with any B-cell malignancy other than myeloma
- •Estimated life expectancy \<6 months
- •Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)
Outcomes
Primary Outcomes
Response to treatment
Time Frame: 24 months
Looking for patient reproted response to treatment with panobinostat
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Completed
Not Applicable
Registry of Patients Treated With Systemic Mold-Active TriazolesInvasive Fungal InfectionNCT03066011Astellas Pharma Global Development, Inc.2,015
Completed
Not Applicable
A Disease Registry of Patients With Mantle Cell LymphomaMantle Cell LymphomaNCT03816683AstraZeneca227
Completed
Not Applicable
Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in TurkeyBipolar DisorderNCT00660712AstraZeneca1,018
Active, not recruiting
Not Applicable
TrEatment Approach in the Multimodal Era RegistryChronic Thromboembolic Pulmonary HypertensionCTEPHNCT05629052International CTEPH Association1,000
Recruiting
Not Applicable
Development and Management of Registry in Patients With Gynecologic Cancer in KoreaCervical CancerEndometrial CancerOvarian CancerFallopian Tube CancerPeritoneal CancerNCT05912972Asan Medical Center13,500